Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Initiates Pivotal Efficacy Trial of KP415
‘Classroom-style’ Pivotal Efficacy Trial of ADHD Prodrug Composition Candidate  to Study Onset and Duration of Efficacy and Product Safety Screening commenced in November; first patient treatment occurred December 20, 2017 CORALVILLE, Iowa , Jan. 08, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA
All Clinical and Non-Clinical Programs Remain on Track for ADHD Prodrug Candidate,  Pivotal Efficacy Trial to Study Duration of Therapy to Initiate Prior to Year-End CORALVILLE, Iowa , Nov. 16, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Filed IND for KP484, A Super-Extended Release ADHD Methylphenidate Prodrug Product Candidate --  KP484 IND Review Completed by FDA ; Cleared to Proceed to Clinical
Toggle Summary KemPharm Receives USAN Approval for “Asalhydromorphone” as Nonproprietary Name for Novel Prodrug Candidate, KP511
Asalhydromorphone’s Physicochemical and Pharmacological Attributes May Offer the Potential to Provide Significant Pain Relief with the Potential of Reduced Opioid Abuse and Misuse CORALVILLE, Iowa , Nov. 06, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company
Toggle Summary KemPharm’s KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies
KP484 Designed to be a Predictably Dosed, “ Super-Extended” Release, Methylphenidate Product Candidate CORALVILLE, Iowa , Nov. 02, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced
Toggle Summary KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD
Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa , Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate
KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa , Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, 
Toggle Summary KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA
FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa , Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of
Toggle Summary KemPharm, Inc. Reports Second Quarter 2017 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights : KP415.109 Pharmacokinetics Phase 1 Trial Completed Held KP415 End-of-Phase 1 Meeting with U.S. Food and Drug Administration ( FDA ) Initiated
Toggle Summary KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial
Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa , Aug. 10, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the